Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239222 · ClinicalTrials.gov registry record · NA
Feasibility Study to Evaluate a New Energy Storage and Return Prosthetic Foot
A NA study, sponsored by Otto Bock Healthcare Products.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT04239222: Completed NA study, sponsored by Otto Bock Healthcare Products.
NCT04239222 is a NA study that has completed, run by Otto Bock Healthcare Products. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04239222, a NA study, has completed, sponsored by Otto Bock Healthcare Products.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
A prospective, interventional, multicenter pilot study to characterize differences in performance and patient reported outcomes between the Taleo, Proflex XC, and the new Revo prosthetic foot.
Primary Outcome
Perception of mobility as measured by the Prosthetic Limb Users Survey of Mobility (PLUS-M) 12-item short form. The PLUS-M questionnaire provides a T-score that ranges from 21.8 to 71.4. Higher PLUS-M scores correspond with greater mobility. The T-score has a mean of 50 and a standard deviation (SD) of 10. A PLUS-M T-score of 50 represents the mean mobility reported by the development sample. A T-score greater than 57 indicates that the mobility is above the 75th percentile.
Interventions
- DEVICE Revo-M
- DEVICE Taleo
- DEVICE Proflex XC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2022-03-11 |
| Phase | NA |
What the finished NCT04239222 record still lists
NCT04239222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Revo-M is the first listed.
NCT04239222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04239222 about?
NCT04239222 is a clinical study titled "Feasibility Study to Evaluate a New Energy Storage and Return Prosthetic Foot". A prospective, interventional, multicenter pilot study to characterize differences in performance and patient reported outcomes between the Taleo, Proflex XC, and the new Revo prosthetic foot.
What is the current status of trial NCT04239222?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2020-03-10. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT04239222?
The interventions under investigation include: Revo-M (DEVICE), Taleo (DEVICE), Proflex XC (DEVICE).
Who is sponsoring clinical trial NCT04239222?
This trial is sponsored by Otto Bock Healthcare Products, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04239222's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI